Compare Bristol-Myers Squibb Co (BMY) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs TKO Group Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while TKO Group Holdings Inc trades at $195.64 (market cap $14.24B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.1× TKO Group Holdings Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | TKO | |
|---|---|---|
Market Cap | $129.94B | $14.24B |
Sector | Health | Technology |
52-Week High | $65.89 | $224.96 |
52-Week Low | $42.60 | $176.49 |
Enterprise Value | $163.92B | $18.60B |
Dividend Yield | 3.96% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
TKO trades at $194.10, up 2.47% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed revenue growth of 18% year-over-year to $1.55 billion, though EPS of $1.34 missed estimates. The company raised full-year guidance, reflecting confidence in media rights and live events. Valuation metrics like a P/E of 68.33 appear elevated relative to earnings.
The outlook is positive given raised guidance and dominant market position in sports entertainment, but high valuation and recent earnings misses pose risks. Upside to the consensus price target of $228.17 suggests potential growth, dependent on execution of growth initiatives and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
